RxDoctor Payments Data

Joseph Lanzi, MD

Orthopaedic Surgery · El Paso, TXNPI 1174722243

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Vericel Corporation accounts for 74.1% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $12,992, 7.5 times the $1,733 reported in 2019.

$39,053in general payments, 2019–2025

Across 157 payments — averaging $248.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vericel Corporation$29K
  • Stryker$4K
  • Linvatec Corporation$2K
  • Rattan And Associates$1K
  • Smith+Nephew$590
  • Zimmer Biomet$580
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$8252%
  • Speaking & faculty fees$14,82538%
  • Travel & lodging$6,76717%
  • Food & beverage$15,43540%
  • Education$1,2003%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,053 in reported general payments places this provider in the 85th percentile of 1,337 orthopaedic surgery providers in Texas.

See all orthopaedic surgery providers in Texas →

Medicare billing

Part B allowed, 2024
$26,578
Medicare patients
56
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Naproxen110$1,154
Gabapentin19$324
Meloxicam42$170
Methocarbamol19$157
Tramadol Hcl15$57

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in El Paso

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →